Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 8/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492413 | 0.85 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL4726269 | 0.85 | GABRA2 (0.47) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2911118 | 0.83 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL16161285 | 0.81 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL2906584 | 0.81 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL2905618 | 0.80 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL2773467 | 0.79 | KDM4E (0.50) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL1703578 | 0.79 | KDM4E (0.50) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2186048 | 0.79 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL2185138 | 0.78 | CNR2 (0.65) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130017149-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-20130017149-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-20130017149-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| EP-2223914-A1 | Tricyclic condensed pyrazole derivatives as CB1 inhibitors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223914-A1 | Tricyclic condensed pyrazole derivatives as CB1 inhibitors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223913-A1 | Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223913-A1 | Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-01 | — | — | EP | disclosed |
| US-20100215741-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215741-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215741-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215741-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, CNR2, TRPV1 | KDM4E 2870/4885MEN1 3516/4885MAPT 1255/4885 |
| US-20130017149-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, CNR2, TRPV1 | KDM4E 2870/4885MEN1 3516/4885MAPT 1255/4885 |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | CNR2, CNR1, SGMS2 | KDM4E 4335/4885MEN1 2015/4885MAPT 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.